In a surprise move, Ipsen (Euronext: IPN) chief executive David Meek (pictured above) has quit his position at the French drugmaker to take the helm at a small gene therapy startup, FerGene.
A subsidiary of Swiss firm Ferring Pharmaceutical, FerGene was founded in November 2019 with a $400 million investment from Blackstone Life Sciences. Ferring put in another $170 million.
The new company is developing nadofaragene firadenovec (rAd-IFN/Syn3), an investigational gene therapy, for certain people with bladder cancer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze